Lumiera Health (TSXV:NHP.H) EBITDA Margin %: -72.84% (As of Aug. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Lumiera Health EBITDA Margin %?

Lumiera Health TSXV:NHP.H EBITDA Margin % is -72.84% as of Aug. 2023.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Lumiera Health's EBITDA for the three months ended in Aug. 2023 was C$-0.06 Mil. Lumiera Health's Revenue for the three months ended in Aug. 2023 was C$0.08 Mil. Therefore, Lumiera Health's EBITDA margin for the quarter that ended in Aug. 2023 was -72.84%.

Lumiera Health  (TSXV:NHP.H) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Lumiera Health EBITDA Margin % Related Terms

Lumiera Health EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Lumiera Health's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lumiera Health EBITDA Margin % Chart

Lumiera Health Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Nov18 Nov19 Nov20 Nov21 Nov22
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -265.36 -335.76 -347.42 86.62 -299.21

Lumiera Health Quarterly Data
Sep18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -208.06 -604.21 -17.39 -53.76 -72.84

TSXV:NHP.H vs ZTS, CTLT, VTRS: EBITDA Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lumiera Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lumiera Health EBITDA Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lumiera Health's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Lumiera Health's EBITDA Margin % falls into.


Lumiera Health EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Lumiera Health's EBITDA Margin % for the fiscal year that ended in Nov. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Nov. 2022 )/Revenue (A: Nov. 2022 )
=-1.888/0.631
=-299.21 %

Lumiera Health's EBITDA Margin % for the quarter that ended in Aug. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Aug. 2023 )/Revenue (Q: Aug. 2023 )
=-0.059/0.081
=-72.84 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -72.84% mean?
Lumiera Health (TSXV:NHP.H) has a EBITDA Margin % of -72.84% as of Aug. 2023. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lumiera Health and its competitors.
Is Lumiera Health's EBITDA Margin % too high?
Lumiera Health's current EBITDA Margin % is -72.84%.
How does Lumiera Health's EBITDA Margin % compare to ZTS and CTLT?
Lumiera Health's EBITDA Margin % of -72.84% can be compared against companies in the Drug Manufacturers industry. The industry median EBITDA Margin % is 12.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lumiera Health and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumiera Health's current EBITDA Margin % is -72.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumiera Health stock overvalued right now?
Lumiera Health (TSXV:NHP.H) has a current EBITDA Margin % of -72.84%. The current EBITDA Margin % is -72.84%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Lumiera Health (TSXV:NHP.H), the current EBITDA Margin % is -72.84% as of Aug. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lumiera Health Business Description

Address 4500 Kimber, Suite 26, Saint-Hubert, QC, CAN, J3Y 8K5
Lumiera Health Inc operates as a product development, marketing and sales business of natural products that outsources the manufacturing of products to third-party manufacturing partners/suppliers. The company sells natural and homeopathic products as well as the development and commercialization of botanical-based products for low-risk agricultural use and human health care.